Analysts expect Artelo Biosciences, Inc. to report revenue of 0.00 for Q3 24, against a range of 0.00 to 0.00. The most recent reported quarter, Q1 25, came in at 0.00.
| Metric | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 | Q2 27 | Q3 27 | Q4 27 | Q1 28 | Q2 28 | Q3 28 | Q4 28 | Q1 29 | Q2 29 | Q3 29 | Q4 29 | Q1 30 | Q2 30 | Q3 30 | Q4 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | - | - | 0.00 | - | - | - | - | - | - | |||||||||||||||||
| High Estimate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||||||||||||||
| Low Estimate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||||||||||||||
| Consensus Estimate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Analysts expect Artelo Biosciences, Inc. to report earnings per share of -6.76 for Q3 26, against a range of -7.13 to -6.39. The most recent reported quarter, Q2 26, came in at -8.01, a 32.4% miss against the -6.05 consensus.
| Metric | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 | Q2 27 | Q3 27 | Q4 27 | Q1 28 | Q2 28 | Q3 28 | Q4 28 | Q1 29 | Q2 29 | Q3 29 | Q4 29 | Q1 30 | Q2 30 | Q3 30 | Q4 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | -56.70 | -189.54 | -116.64 | -151.47 | -107.19 | -59.94 | -36.00 | -8.01 | - | - | - | - | - | - | - | - | ||||||||||
| High Estimate | -115.25 | -64.25 | -19.18 | -110.95 | -20.04 | -37.46 | -7.09 | -5.77 | -6.39 | -7.13 | -3.75 | -3.06 | 12.90 | 13.70 | 24.96 | 28.24 | ||||||||||
| Low Estimate | -136.33 | -73.31 | -22.88 | -127.51 | -22.22 | -41.50 | -7.91 | -6.33 | -7.13 | -7.73 | -4.13 | -3.72 | 10.78 | 11.26 | 21.44 | 23.50 | ||||||||||
| Consensus Estimate | -125.79 | -68.78 | -21.03 | -119.23 | -21.13 | -39.48 | -7.50 | -6.05 | -6.76 | -7.43 | -3.94 | -3.39 | 11.84 | 12.48 | 23.20 | 25.87 |